Tom Oppelt

Tom Oppelt is a seasoned professional in the pharmaceutical industry, currently serving as the US Medical Affairs Senior Medical Director and Strategy Lead for Emerging Viruses and COVID-19 at Gilead Sciences since June 2021. With a career at Gilead spanning over a decade, Tom has played pivotal roles in various capacities, including leading strategy initiatives for product development and clinical research in emerging viruses, inflammation, and cardiovascular diseases. Prior to joining Gilead, Tom held multiple leadership positions at Novartis, focusing on health economics, outcomes research, and scientific operations. Tom began a career in academia as a Clinical Associate Professor at the University of South Carolina, where responsibility included course coordination and supervising pharmacy students. Tom holds a PharmD from Campbell University and a BS in Business Administration from the University of North Carolina Wilmington.